Endocrine therapy remains a cornerstone of treating estrogen receptor alpha (ERα)-positive breast tumors by blocking the agonistic effects of estrogen, either by directly antagonizing receptor binding or by blocking its production with aromatase inhibitors. This evidence concerns the gene ESR1 and breast neoplasm.